Skip to main content

Advertisement

SpringerLink
Log in

Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

A Correction to this article was published on 25 September 2020

This article has been updated

Abstract

Mesalazine formulations are essential for treating ulcerative colitis (UC), and intolerance to these formulations complicates the treatment of this condition. Some cases of mesalazine formulation intolerance are caused by the excipients rather than the active ingredient mesalazine. Therefore, mesalazine administration can be continued in such cases by changing the mesalazine formulation. This report describes a case of intolerance to mesalazine in which UC was effectively treated by switching mesalazine formulations. A drug-induced lymphocyte stimulation test suggested that allergy to the additive povidone was the cause of mesalazine formulation intolerance. This is the first case study to identify an additive that caused mesalazine formulation intolerance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Change history

  • 25 September 2020

    The article “Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report”, written by Yoshinori Arai, Maiko Ogawa, Fumitsugu Yamane, Natsuki Sumiyoshi, Rikako Arimoto.

References

  1. Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am. 2014;24:367–78.

    PubMed  Google Scholar 

  2. Langhorst J, Lauche R. It is about time: tailoring of an individualized multimodal treatment approach in ulcerative colitis. Digestion. 2014;89:139–41.

    CAS  PubMed  Google Scholar 

  3. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–25.

    CAS  PubMed  Google Scholar 

  4. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–78.

    PubMed  Google Scholar 

  5. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441–522.

    CAS  PubMed  Google Scholar 

  6. Okayasu I. Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. Pathol Int. 2012;62:368–80.

    CAS  PubMed  Google Scholar 

  7. Flourie B, Hagege H, Tucat G, et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther. 2013;37:767–75.

    CAS  PubMed  Google Scholar 

  8. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:601–16.

    CAS  PubMed  Google Scholar 

  9. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC maintenance study group. Dig Dis Sci. 1995;40:296–304.

    CAS  PubMed  Google Scholar 

  10. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group Am J Gastroenterol. 1993;88:1188–97.

    CAS  Google Scholar 

  11. Shimodate Y, Takanashi K, Waga E, et al. Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis. Case Rep Gastroenterol. 2011;5:159–65.

    PubMed  PubMed Central  Google Scholar 

  12. Iofel E, Chawla A, Daum F, et al. Mesalamine intolerance mimics symptoms of active inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;34:73–6.

    PubMed  Google Scholar 

  13. Saito D, Hayashida M, Sato T, et al. Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy. Intest Res. 2018;16:273–81.

    PubMed  PubMed Central  Google Scholar 

  14. Gonzalo Garijo MA, Durán Quintana JA, Bobadilla González P, et al. Anaphylactic shock following povidone. Ann Pharmacother. 1996;30:37–40.

    CAS  PubMed  Google Scholar 

  15. Pedrosa C, Costa H, Oliveira G, et al. Anaphylaxis to povidone in a child. Pediatr Allergy Immunol. 2005;16:361–2.

    CAS  PubMed  Google Scholar 

  16. Le Pabic F, Sainte-Laudy J, Blanchard N, et al. First case of anaphylaxis to iodinated povidone. Allergy. 2003;58:826–7.

    PubMed  Google Scholar 

Download references

Acknowledgements

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Katsushika Medical Center, -41-2 Aoto, Katsushika-ku, Tokyo, 105-8461, Japan

    Yoshinori Arai, Maiko Ogawa, Fumitsugu Yamane, Natsuki Sumiyoshi, Rikako Arimoto, Yoshitaka Ando, Daisuke Endo, Tatsuya Nakada, Ichiro Sugawara, Hiroshi Yokoyama, Seiji Arihiro & Atsushi Hokari

  2. Department of Endoscopy, The Jikei University Katsushika Medical Center, Tokyo, Japan

    Keiko Shimoyama, Hiroko Inomata, Yosuke Kawahara & Masayuki Kato

  3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

    Masayuki Saruta

Authors
  1. Yoshinori Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maiko Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumitsugu Yamane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natsuki Sumiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rikako Arimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitaka Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daisuke Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tatsuya Nakada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ichiro Sugawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroshi Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Keiko Shimoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroko Inomata
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yosuke Kawahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masayuki Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Seiji Arihiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Atsushi Hokari
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Masayuki Saruta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshinori Arai.

Ethics declarations

Conflict of interest

Yoshinori Arai, Maiko Ogawa, Fumitsugu Yamane, Natsuki Sumiyoshi, Rikako Arimoto, Yoshitaka Ando, Daisuke Endo, Tatsuya Nakada, Ichiro Sugawara, Hiroshi Yokoyama, Keiko Shimoyama, Hiroko Inomata, Yosuke Kawahara, Masayuki Kato, Seiji Arihiro, Atsushi Hokari, and Masayuki Saruta declare that they have no conflict of interest.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from the patient for being included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised due to retrospective Open Access cancellation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arai, Y., Ogawa, M., Yamane, F. et al. Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report. Clin J Gastroenterol 13, 1200–1204 (2020). https://doi.org/10.1007/s12328-020-01216-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-020-01216-2

Keywords

Search

Navigation